{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "table = pd.read_excel('glioma_studies.xlsx')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Trialtrove Trial Count</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>363</th>\n",
       "      <td>2524</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>366</th>\n",
       "      <td>2484</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60</th>\n",
       "      <td>2254</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>125</th>\n",
       "      <td>2166</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>286</th>\n",
       "      <td>1744</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>342</th>\n",
       "      <td>1136</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>1044</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>379</th>\n",
       "      <td>1038</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>137</th>\n",
       "      <td>990</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>428</th>\n",
       "      <td>961</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>207</th>\n",
       "      <td>955</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>209</th>\n",
       "      <td>929</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>467</th>\n",
       "      <td>919</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>380</th>\n",
       "      <td>829</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>443</th>\n",
       "      <td>813</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>266</th>\n",
       "      <td>792</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>220</th>\n",
       "      <td>663</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>452</th>\n",
       "      <td>622</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>434</th>\n",
       "      <td>579</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>283</th>\n",
       "      <td>529</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>187</th>\n",
       "      <td>460</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>460</th>\n",
       "      <td>421</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>163</th>\n",
       "      <td>378</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>301</th>\n",
       "      <td>352</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>182</th>\n",
       "      <td>338</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>369</th>\n",
       "      <td>302</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>375</th>\n",
       "      <td>293</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>291</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>352</th>\n",
       "      <td>287</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>446</th>\n",
       "      <td>237</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>232</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>306</th>\n",
       "      <td>192</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>276</th>\n",
       "      <td>190</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>399</th>\n",
       "      <td>189</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>114</th>\n",
       "      <td>185</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>465</th>\n",
       "      <td>178</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>173</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>278</th>\n",
       "      <td>173</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>340</th>\n",
       "      <td>171</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>200</th>\n",
       "      <td>169</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>337</th>\n",
       "      <td>157</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>149</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>150</th>\n",
       "      <td>146</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>398</th>\n",
       "      <td>144</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>388</th>\n",
       "      <td>140</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>113</th>\n",
       "      <td>139</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>462</th>\n",
       "      <td>137</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>483</th>\n",
       "      <td>137</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>275</th>\n",
       "      <td>134</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>479</th>\n",
       "      <td>125</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     Trialtrove Trial Count\n",
       "363                    2524\n",
       "366                    2484\n",
       "60                     2254\n",
       "125                    2166\n",
       "286                    1744\n",
       "342                    1136\n",
       "98                     1044\n",
       "379                    1038\n",
       "137                     990\n",
       "428                     961\n",
       "207                     955\n",
       "209                     929\n",
       "467                     919\n",
       "380                     829\n",
       "443                     813\n",
       "266                     792\n",
       "220                     663\n",
       "452                     622\n",
       "434                     579\n",
       "283                     529\n",
       "187                     460\n",
       "460                     421\n",
       "163                     378\n",
       "301                     352\n",
       "182                     338\n",
       "369                     302\n",
       "375                     293\n",
       "58                      291\n",
       "352                     287\n",
       "446                     237\n",
       "15                      232\n",
       "306                     192\n",
       "276                     190\n",
       "399                     189\n",
       "114                     185\n",
       "465                     178\n",
       "16                      173\n",
       "278                     173\n",
       "340                     171\n",
       "200                     169\n",
       "337                     157\n",
       "52                      149\n",
       "150                     146\n",
       "398                     144\n",
       "388                     140\n",
       "113                     139\n",
       "462                     137\n",
       "483                     137\n",
       "275                     134\n",
       "479                     125"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "table[['Trialtrove Trial Count']].sort_values(by='Trialtrove Trial Count', ascending=False).head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['Generic Drug Name', 'Drug Names', 'Summary', 'Global Status',\n",
       "       'Development Status', 'Drug Disease', 'Company',\n",
       "       'Originator / Licensee', 'Company HQ Country', 'Company HQ State',\n",
       "       'Company (Subsidiary/Acquiree)',\n",
       "       'Company (Subsidiary/Acquiree) HQ Country',\n",
       "       'Company (Subsidiary/Acquiree) HQ State', 'Drug Country',\n",
       "       'Drug Country Region', 'Current Status', 'Launch Year',\n",
       "       'Highest Status Reached', 'Partnering Availability: Country',\n",
       "       'Latest Change Date', 'Latest Change', 'Event Date', 'Event Type',\n",
       "       'Event Details', 'Therapeutic Class', 'Therapeutic Class Status',\n",
       "       'Mechanism Of Action', 'Delivery Route', 'Delivery Medium',\n",
       "       'Delivery Technology', 'Target', 'Target Entrez Gene ID',\n",
       "       'Target Family', 'Target EC Number', 'Trialtrove Trial Count', 'Origin',\n",
       "       'NCE', 'Molecular Weight', 'Chemical Name',\n",
       "       'Chemical structure (SMILES format)', 'Molecular Formula', 'CAS Number',\n",
       "       'LogP', 'H Bond Donors', 'H Bond Acceptors', 'Rotatable Bonds',\n",
       "       'Patent Number', 'Patent Priority Country & Date', 'Marketing',\n",
       "       'Licensing', 'Phase III', 'Phase II', 'Phase I', 'Preclinical',\n",
       "       'Record URL'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "table.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 510 entries, 0 to 509\n",
      "Data columns (total 55 columns):\n",
      " #   Column                                    Non-Null Count  Dtype         \n",
      "---  ------                                    --------------  -----         \n",
      " 0   Generic Drug Name                         510 non-null    object        \n",
      " 1   Drug Names                                510 non-null    object        \n",
      " 2   Summary                                   510 non-null    object        \n",
      " 3   Global Status                             510 non-null    object        \n",
      " 4   Development Status                        510 non-null    object        \n",
      " 5   Drug Disease                              510 non-null    object        \n",
      " 6   Company                                   510 non-null    object        \n",
      " 7   Originator / Licensee                     510 non-null    object        \n",
      " 8   Company HQ Country                        510 non-null    object        \n",
      " 9   Company HQ State                          510 non-null    object        \n",
      " 10  Company (Subsidiary/Acquiree)             510 non-null    object        \n",
      " 11  Company (Subsidiary/Acquiree) HQ Country  510 non-null    object        \n",
      " 12  Company (Subsidiary/Acquiree) HQ State    510 non-null    object        \n",
      " 13  Drug Country                              510 non-null    object        \n",
      " 14  Drug Country Region                       510 non-null    object        \n",
      " 15  Current Status                            510 non-null    object        \n",
      " 16  Launch Year                               510 non-null    object        \n",
      " 17  Highest Status Reached                    510 non-null    object        \n",
      " 18  Partnering Availability: Country          73 non-null     object        \n",
      " 19  Latest Change Date                        510 non-null    datetime64[ns]\n",
      " 20  Latest Change                             510 non-null    object        \n",
      " 21  Event Date                                506 non-null    object        \n",
      " 22  Event Type                                506 non-null    object        \n",
      " 23  Event Details                             506 non-null    object        \n",
      " 24  Therapeutic Class                         510 non-null    object        \n",
      " 25  Therapeutic Class Status                  510 non-null    object        \n",
      " 26  Mechanism Of Action                       510 non-null    object        \n",
      " 27  Delivery Route                            510 non-null    object        \n",
      " 28  Delivery Medium                           170 non-null    object        \n",
      " 29  Delivery Technology                       38 non-null     object        \n",
      " 30  Target                                    510 non-null    object        \n",
      " 31  Target Entrez Gene ID                     510 non-null    object        \n",
      " 32  Target Family                             510 non-null    object        \n",
      " 33  Target EC Number                          510 non-null    object        \n",
      " 34  Trialtrove Trial Count                    510 non-null    int64         \n",
      " 35  Origin                                    510 non-null    object        \n",
      " 36  NCE                                       510 non-null    object        \n",
      " 37  Molecular Weight                          152 non-null    float64       \n",
      " 38  Chemical Name                             218 non-null    object        \n",
      " 39  Chemical structure (SMILES format)        152 non-null    object        \n",
      " 40  Molecular Formula                         152 non-null    object        \n",
      " 41  CAS Number                                194 non-null    object        \n",
      " 42  LogP                                      146 non-null    float64       \n",
      " 43  H Bond Donors                             146 non-null    float64       \n",
      " 44  H Bond Acceptors                          146 non-null    float64       \n",
      " 45  Rotatable Bonds                           146 non-null    float64       \n",
      " 46  Patent Number                             99 non-null     object        \n",
      " 47  Patent Priority Country & Date            99 non-null     object        \n",
      " 48  Marketing                                 510 non-null    object        \n",
      " 49  Licensing                                 510 non-null    object        \n",
      " 50  Phase III                                 510 non-null    object        \n",
      " 51  Phase II                                  510 non-null    object        \n",
      " 52  Phase I                                   510 non-null    object        \n",
      " 53  Preclinical                               510 non-null    object        \n",
      " 54  Record URL                                510 non-null    object        \n",
      "dtypes: datetime64[ns](1), float64(5), int64(1), object(48)\n",
      "memory usage: 219.3+ KB\n"
     ]
    }
   ],
   "source": [
    "table.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Trialtrove Trial Count</th>\n",
       "      <th>Molecular Weight</th>\n",
       "      <th>LogP</th>\n",
       "      <th>H Bond Donors</th>\n",
       "      <th>H Bond Acceptors</th>\n",
       "      <th>Rotatable Bonds</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>510.000000</td>\n",
       "      <td>152.000000</td>\n",
       "      <td>146.000000</td>\n",
       "      <td>146.000000</td>\n",
       "      <td>146.000000</td>\n",
       "      <td>146.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>68.372549</td>\n",
       "      <td>455.933487</td>\n",
       "      <td>3.002945</td>\n",
       "      <td>2.205479</td>\n",
       "      <td>5.773973</td>\n",
       "      <td>6.171233</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>267.026540</td>\n",
       "      <td>171.167112</td>\n",
       "      <td>2.690517</td>\n",
       "      <td>1.570933</td>\n",
       "      <td>2.897729</td>\n",
       "      <td>4.394918</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>0.000000</td>\n",
       "      <td>47.060000</td>\n",
       "      <td>-3.780000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>0.000000</td>\n",
       "      <td>356.007500</td>\n",
       "      <td>1.400000</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>4.000000</td>\n",
       "      <td>4.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>3.000000</td>\n",
       "      <td>447.200000</td>\n",
       "      <td>3.025000</td>\n",
       "      <td>2.000000</td>\n",
       "      <td>5.000000</td>\n",
       "      <td>5.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>13.000000</td>\n",
       "      <td>543.520000</td>\n",
       "      <td>4.370000</td>\n",
       "      <td>3.000000</td>\n",
       "      <td>7.000000</td>\n",
       "      <td>8.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>2524.000000</td>\n",
       "      <td>1030.300000</td>\n",
       "      <td>17.160000</td>\n",
       "      <td>7.000000</td>\n",
       "      <td>14.000000</td>\n",
       "      <td>31.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       Trialtrove Trial Count  Molecular Weight        LogP  H Bond Donors  \\\n",
       "count              510.000000        152.000000  146.000000     146.000000   \n",
       "mean                68.372549        455.933487    3.002945       2.205479   \n",
       "std                267.026540        171.167112    2.690517       1.570933   \n",
       "min                  0.000000         47.060000   -3.780000       0.000000   \n",
       "25%                  0.000000        356.007500    1.400000       1.000000   \n",
       "50%                  3.000000        447.200000    3.025000       2.000000   \n",
       "75%                 13.000000        543.520000    4.370000       3.000000   \n",
       "max               2524.000000       1030.300000   17.160000       7.000000   \n",
       "\n",
       "       H Bond Acceptors  Rotatable Bonds  \n",
       "count        146.000000       146.000000  \n",
       "mean           5.773973         6.171233  \n",
       "std            2.897729         4.394918  \n",
       "min            0.000000         0.000000  \n",
       "25%            4.000000         4.000000  \n",
       "50%            5.000000         5.000000  \n",
       "75%            7.000000         8.000000  \n",
       "max           14.000000        31.000000  "
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "table.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Radiopharmaceutical; Integrin antagonist', 'Radiopharmaceutical',\n",
       "       'Unidentified pharmacological activity',\n",
       "       'Neurotensin receptor antagonist',\n",
       "       'Glycogen synthase kinase 3 inhibitor',\n",
       "       'Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor',\n",
       "       'Vascular endothelial growth factor (VEGF)receptor antagonist; Delta-like 4 antagonist',\n",
       "       'mTORC1 kinase inhibitor; mTORC2 kinase inhibitor; Protein kinase B inhibitor; PI3 kinase inhibitor',\n",
       "       'Bruton tyrosine kinase inhibitor', 'Immuno-oncology therapy',\n",
       "       'Immuno-oncology therapy; Immunostimulant; T cell stimulant',\n",
       "       'EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI)',\n",
       "       'Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor',\n",
       "       'Thymidine kinase stimulant; DNA directed DNA polymerase inhibitor; Immunostimulant',\n",
       "       'Radical formation stimulant', 'DNA topoisomerase II inhibitor',\n",
       "       'Immuno-oncology therapy; CD3 agonist',\n",
       "       'Taxane; Beta tubulin inhibitor; Microtubule stimulant',\n",
       "       'Survivin inhibitor; Immuno-oncology therapy', 'Not applicable',\n",
       "       'Immuno-oncology therapy; T cell stimulant',\n",
       "       'Semaphorin 3A antagonist',\n",
       "       'T cell stimulant; Immuno-oncology therapy', 'Immunostimulant',\n",
       "       'CD40 agonist; Immune checkpoint stimulant; Immuno-oncology therapy',\n",
       "       'Taxane; Microtubule stimulant; Beta tubulin inhibitor',\n",
       "       'Maternal embryonic leucine zipper kinase inhibitor',\n",
       "       'Apoptosis stimulant; Cell cycle inhibitor',\n",
       "       'DNA repair enzyme inhibitor',\n",
       "       'Immunosuppressant; Apoptosis inhibitor',\n",
       "       'Bcl2 inhibitor; Bcl-XL inhibitor; Mcl-1 antagonist',\n",
       "       'PCNA inhibitor', 'Cereblon agonist',\n",
       "       'VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; C-kit inhibitor; Angiogenesis inhibitor; Platelet-derived growth factor receptor beta kinase inhib',\n",
       "       'ATM kinase inhibitor',\n",
       "       'Microtubule inhibitor; Tubulin inhibitor; Apoptosis stimulant',\n",
       "       'Phosphatidylserine inhibitor; Immuno-oncology therapy',\n",
       "       'Lysine (K)-specific demethylase 1A inhibitor',\n",
       "       'DNA inhibitor; Apoptosis stimulant',\n",
       "       'Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor; Immuno-oncology therapy',\n",
       "       'Vascular endothelial growth factor (VEGF)receptor antagonist; Angiopoietin inhibitor',\n",
       "       'Cyclin-dependent kinase inhibitor',\n",
       "       'PI3 kinase inhibitor; mTOR kinase inhibitor',\n",
       "       'Mitogen-activated kinase kinase inhibitor',\n",
       "       'Radiopharmaceutical; DNA inhibitor',\n",
       "       'Proteasome inhibitor; Transcription factor NF-kappaB inhibitor; Apoptosis stimulant',\n",
       "       'Src inhibitor; Bcr-Abl inhibitor; Apoptosis stimulant; Abl receptor tyrosine kinase inhibitor',\n",
       "       'MET tyrosine kinase inhibitor',\n",
       "       'PI3 kinase inhibitor; Protein kinase inhibitor',\n",
       "       'Immunostimulant; Immuno-oncology therapy',\n",
       "       'Gene expression inhibitor', 'Taxane; Microtubule inhibitor',\n",
       "       'MET tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; RET tyrosine kinase inhibitor; VEGFR tyrosine kinase inhibitor; Axl receptor tyrosine kinase inhibitor',\n",
       "       'Colony stimulating factor 1 receptor antagonist',\n",
       "       'Direct thrombin inhibitor',\n",
       "       'Vanilloid receptor 1 agonist; GPR55 antagonist; Cannabinoid CB1 receptor agonist; Cannabinoid CB2 receptor agonist; Adenosine uptake inhibitor; Cannabinoid CB1 receptor inverse agonist',\n",
       "       'Vanilloid receptor 1 agonist; GPR55 antagonist; Adenosine uptake inhibitor; Cannabinoid CB1 receptor inverse agonist',\n",
       "       'Cannabinoid CB1 receptor inverse agonist; Vanilloid receptor 1 agonist; GPR55 antagonist; Adenosine uptake inhibitor',\n",
       "       'Cannabinoid receptor agonist',\n",
       "       'Thymidylate synthase inhibitor; DNA synthesis inhibitor; RNA synthesis inhibitor',\n",
       "       'DNA inhibitor',\n",
       "       'DNA-dependent protein kinase inhibitor; mTORC1 kinase inhibitor; mTORC2 kinase inhibitor',\n",
       "       'BET protein inhibitor',\n",
       "       'CD200 antagonist; Immuno-oncology therapy; Immune checkpoint inhibitor',\n",
       "       'VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; C-kit inhibitor; Angiogenesis inhibitor; VEGFR tyrosine kinase inhibitor',\n",
       "       'PD-1 antagonist; Immune checkpoint inhibitor; Immuno-oncology therapy',\n",
       "       'Anaplastic lymphoma kinase inhibitor', 'EGFR antagonist',\n",
       "       'T cell stimulant; Immuno-oncology therapy; PD-1 antagonist',\n",
       "       'DNA inhibitor; Radiopharmaceutical',\n",
       "       'Transcription factor NF-kappaB inhibitor; Toll-like receptor 9 agonist',\n",
       "       'Caspase 9 stimulant; Apoptosis stimulant; p53 stimulant',\n",
       "       'Notch pathway inhibitor; Secretase gamma inhibitor',\n",
       "       'Platelet-derived growth factor receptor alpha kinase inhib; Platelet-derived growth factor receptor beta kinase inhib; Angiogenesis inhibitor; Flt-3 antagonist',\n",
       "       'Anaplastic lymphoma kinase inhibitor; MET tyrosine kinase inhibitor',\n",
       "       'Oligodendrocyte lineage transcription factor 2 inhibitor',\n",
       "       'T cell stimulant; Immuno-oncology therapy; Genome editing',\n",
       "       'Poly ADP ribose polymerase inhibitor',\n",
       "       'Natural killer cell stimulant; Immuno-oncology therapy',\n",
       "       'DNA synthesis inhibitor', 'B-raf kinase inhibitor',\n",
       "       'EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-4 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI)',\n",
       "       'PI3 kinase inhibitor; mTORC1 kinase inhibitor; mTORC2 kinase inhibitor; Protein kinase inhibitor',\n",
       "       'RNA synthesis inhibitor; Radical formation stimulant; DNA topoisomerase II inhibitor',\n",
       "       'Bcr-Abl inhibitor; Src inhibitor; C-kit inhibitor; EphA receptor kinase inhibitor; Fyn tyrosine kinase inhibitor; Yes tyrosine kinase inhibitor; LYN tyrosine kinase inhibitor; Lymphocyte-specific tyrosine kinase inhibitor; Platelet-derived growth factor receptor beta kinase inhib',\n",
       "       'Raf kinase inhibitor', 'T cell stimulant',\n",
       "       'Immuno-oncology therapy; Tumour necrosis factor ligand 4 agonist',\n",
       "       'Chemokine receptor antagonist; Proteasome inhibitor',\n",
       "       'Chemokine receptor antagonist',\n",
       "       'DNA topoisomerase II inhibitor; Immunostimulant',\n",
       "       'DNA topoisomerase II inhibitor; DNA synthesis inhibitor; RNA synthesis inhibitor',\n",
       "       'Radiopharmaceutical; Immuno-oncology therapy',\n",
       "       'Isocitrate dehydrogenase 1 inhibitor',\n",
       "       'Microtubule inhibitor; DNA inhibitor; DNA synthesis inhibitor',\n",
       "       'PD-L1 antagonist; Immune checkpoint inhibitor; Immuno-oncology therapy',\n",
       "       'Mitogen-activated kinase kinase inhibitor; Protein kinase inhibitor; Flt-3 antagonist',\n",
       "       'IKK2 inhibitor; Flt-3 antagonist; Pim kinase inhibitor',\n",
       "       'Ornithine decarboxylase inhibitor',\n",
       "       'Interleukin 12 agonist; Immuno-oncology therapy',\n",
       "       'sequestosome 1 inhibitor; Immunostimulant; Immuno-oncology therapy',\n",
       "       'Isocitrate dehydrogenase 2 inhibitor', 'Angiogenesis inhibitor',\n",
       "       'Protein kinase C beta inhibitor; Angiogenesis inhibitor; Apoptosis stimulant',\n",
       "       'Immuno-oncology therapy; Microbiome modulator',\n",
       "       'EGFR kinase inhibitor',\n",
       "       'EGFR kinase inhibitor; Tyrosine kinase inhibitor (TKI)',\n",
       "       'DNA topoisomerase I inhibitor',\n",
       "       'mTOR kinase inhibitor; Angiogenesis inhibitor; Cell cycle inhibitor; Immunosuppressant; Protein kinase inhibitor',\n",
       "       'DNA inhibitor; DNA synthesis inhibitor',\n",
       "       'Tumour necrosis factor alpha agonist',\n",
       "       'Hepatocyte growth factor receptor antagonist',\n",
       "       'Tubulin inhibitor; VE-cadherin antagonist; Angiogenesis inhibitor; Microtubule inhibitor; Apoptosis stimulant; Immuno-oncology therapy',\n",
       "       'Epidermal growth factor antagonist; Immuno-oncology therapy',\n",
       "       'Immunostimulant; T cell stimulant; Immuno-oncology therapy',\n",
       "       'Transforming growth factor beta receptor 1 antagonist; Protein kinase inhibitor',\n",
       "       'TRAIL receptor 2 agonist',\n",
       "       'ELAVL1 inhibitor; Gene expression inhibitor',\n",
       "       'Nicotinamide N-methyltransferase inhibitor',\n",
       "       'Histone deacetylase inhibitor',\n",
       "       'ErbB-2 antagonist; Immuno-oncology therapy; T cell stimulant',\n",
       "       'ErbB-2 antagonist; Immuno-oncology therapy', 'AMPK stimulant',\n",
       "       'Bone morphogenetic protein 4 stimulant',\n",
       "       'B7-H3 antagonist; Immune checkpoint inhibitor; Immuno-oncology therapy',\n",
       "       'Interleukin 8 antagonist; Immuno-oncology therapy',\n",
       "       'Heat shock protein 90 antagonist; Angiogenesis inhibitor',\n",
       "       'Phosphodiesterase 4 inhibitor; Leucotriene receptor antagonist; Nitric oxide synthase inhibitor; Phosphodiesterase 10A inhibitor; Phosphodiesterase 11 inhibitor; Macrophage migration inhibiting factor inhibitor; Toll-like receptor 4 antagonist',\n",
       "       'Toll-like receptor 4 agonist; Immuno-oncology therapy; Immunostimulant',\n",
       "       'DNA topoisomerase II inhibitor; 5 Alpha reductase inhibitor; Sphingosine kinase inhibitor; tNOX inhibitor; Caspase 8 inhibitor; IAP antagonist; Immune checkpoint inhibitor; STING agonist',\n",
       "       'EphA receptor kinase inhibitor',\n",
       "       'T cell stimulant; Interleukin 7 agonist; Immuno-oncology therapy',\n",
       "       'Bcr-Abl inhibitor; Platelet-derived growth factor receptor kinase inhibitor; C-kit inhibitor; Apoptosis stimulant',\n",
       "       'Telomerase inhibitor; RNA binder',\n",
       "       'Indoleamine 2,3-dioxygenase inhibitor; Immune checkpoint inhibitor; Immuno-oncology therapy',\n",
       "       'FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor',\n",
       "       'Interferon alpha 2A agonist',\n",
       "       'Interferon alpha 2b agonist; Immunostimulant',\n",
       "       'Interferon alpha 2b agonist; RNA synthesis inhibitor; Protein synthesis inhibitor; Immunosuppressant; Interferon receptor agonist',\n",
       "       'Interferon beta 1 agonist',\n",
       "       'Interferon beta 1 agonist; Interferon receptor agonist',\n",
       "       'Interferon beta agonist; Protein synthesis inhibitor',\n",
       "       'Interferon beta agonist', 'Interleukin 2 agonist',\n",
       "       'Interleukin 12 agonist; Immuno-oncology therapy; Immune checkpoint inhibitor',\n",
       "       'CTLA4 antagonist; Immune checkpoint inhibitor; Immuno-oncology therapy',\n",
       "       'DNA synthesis inhibitor; DNA inhibitor; Apoptosis stimulant; RNA polymerase inhibitor',\n",
       "       'Apoptosis stimulant; DNA inhibitor; DNA synthesis inhibitor',\n",
       "       'Preferential antigen of melanoma inhibitor; Immuno-oncology therapy',\n",
       "       'CD38 antagonist; Immuno-oncology therapy; Immunostimulant',\n",
       "       'Arginine methyltransferase inhibitor',\n",
       "       'Src inhibitor; Tubulin polymerization inhibitor',\n",
       "       'MicroRNA inhibitor',\n",
       "       'ErbB-2 tyrosine kinase inhibitor; Epidermal growth factor antagonist; Tyrosine kinase inhibitor (TKI); EGFR kinase inhibitor',\n",
       "       'TrkA tyrosine kinase inhibitor',\n",
       "       'Protein phosphatase 2A inhibitor', 'Microtubule inhibitor',\n",
       "       'VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; FGF receptor 4 tyrosine kinase inhibitor; C-kit inhibitor; Platelet-derived growth factor receptor alpha kinase inhib; RET tyrosine kinase inhibitor; Angiogenesis inhibitor; Angiopoietin inhibitor',\n",
       "       'Sphingomyelinase stimulant; Immunostimulant',\n",
       "       'Immunostimulant; ErbB-2 antagonist',\n",
       "       'sphingomyelin synthase 1 stimulant',\n",
       "       'Endothelin A receptor antagonist; Endothelin B receptor antagonist',\n",
       "       'Proteasome inhibitor; Apoptosis stimulant',\n",
       "       'Platelet-derived growth factor receptor kinase inhibitor; C-kit inhibitor; FGF receptor 3 tyrosine kinase inhibitor; LYN tyrosine kinase inhibitor; Fyn tyrosine kinase inhibitor; Colony stimulating factor 1 receptor antagonist',\n",
       "       'Interleukin 13 receptor antagonist',\n",
       "       'Protein synthesis inhibitor; Interleukin 4 receptor antagonist; Immuno-oncology therapy',\n",
       "       'Immuno-oncology therapy; Immunostimulant',\n",
       "       'Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 5 inhibitor; Cyclin-dependent kinase 7 inhibitor; TrkA tyrosine kinase inhibitor',\n",
       "       'DNA synthesis inhibitor; DNA inhibitor',\n",
       "       'Immuno-oncology therapy; CD4 agonist',\n",
       "       'Immuno-oncology therapy; Immunostimulant; CD4 agonist',\n",
       "       'mTOR kinase inhibitor; Cell cycle inhibitor; Immunosuppressant; Protein kinase inhibitor; T cell inhibitor; Angiogenesis inhibitor',\n",
       "       'Cannabinoid CB1 receptor agonist',\n",
       "       'Apoptosis stimulant; Immuno-oncology therapy',\n",
       "       'STAT transcription factor 3 inhibitor; Apoptosis stimulant',\n",
       "       'Dual specificity protein kinase inhibitor',\n",
       "       'Beta tubulin inhibitor',\n",
       "       'MET tyrosine kinase inhibitor; Axl receptor tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; Macrophage stimulating protein 1 receptor antagonist; Mer tyrosine kinase inhibitor; Flt-3 antagonist',\n",
       "       'VEGFR-2 tyrosine kinase inhibitor; Angiogenesis inhibitor; Platelet-derived growth factor receptor kinase inhibitor; Src inhibitor; Lymphocyte-specific tyrosine kinase inhibitor; LYN tyrosine kinase inhibitor; FGF receptor tyrosine kinase inhibitor; VEGFR tyrosine kinase inhibitor',\n",
       "       'Poly ADP ribose polymerase 1 inhibitor; Poly ADP ribose polymerase 2 inhibitor; DNA repair enzyme inhibitor',\n",
       "       'Poly ADP ribose polymerase 1 inhibitor; DNA repair enzyme inhibitor',\n",
       "       'Stem cell growth factor agonist',\n",
       "       'Aldehyde dehydrogenase inhibitor; NADH dehydrogenase (ubiquinone) inhibitor',\n",
       "       'Arginase I inhibitor; Arginase II inhibitor; Immuno-oncology therapy; Immune checkpoint modulator',\n",
       "       'Fas agonist; Apoptosis stimulant; Angiogenesis inhibitor; Immuno-oncology therapy',\n",
       "       'Poly ADP ribose polymerase 1 inhibitor; Poly ADP ribose polymerase 2 inhibitor',\n",
       "       'Stromal cell-derived factor 1 antagonist; Angiogenesis inhibitor',\n",
       "       'Platelet-derived growth factor (PDGF) receptor antagonist',\n",
       "       'Vascular endothelial growth factor receptor 2 antagonist; Angiogenesis inhibitor',\n",
       "       'B7-H3 antagonist; DNA inhibitor; Immune checkpoint inhibitor; Immuno-oncology therapy; Radiopharmaceutical',\n",
       "       'B7-H3 antagonist; Immune checkpoint inhibitor; Immuno-oncology therapy; Radiopharmaceutical',\n",
       "       'Heat shock protein 90 antagonist',\n",
       "       'mTORC1 kinase inhibitor; mTORC2 kinase inhibitor',\n",
       "       'TRAIL receptor agonist; Dopamine D2 receptor antagonist',\n",
       "       'Beta1 integrin antagonist',\n",
       "       'L-type amino acid transporter 1 inhibitor; Radiopharmaceutical',\n",
       "       'Caspase 3 stimulant; Apoptosis stimulant',\n",
       "       'Hypoxia-inducible factor 1 antagonist; Vascular endothelial growth factor (VEGF)receptor antagonist; Apoptosis stimulant; Angiopoietin inhibitor; mTORC1 kinase inhibitor; mTORC2 kinase inhibitor; PI3 kinase inhibitor',\n",
       "       'Histone deacetylase inhibitor; Apoptosis stimulant; Cell cycle inhibitor',\n",
       "       'Mitotic inhibitor; Immuno-oncology therapy',\n",
       "       'PI3 kinase inhibitor; mTOR kinase inhibitor; Protein kinase B inhibitor',\n",
       "       'VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; C-kit inhibitor; Angiogenesis inhibitor; VEGFR tyrosine kinase inhibitor; B-raf kinase inhibitor; FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor',\n",
       "       'Protein kinase B inhibitor; Fibroblast growth factor 2 antagonist; Transcription factor NF-kappaB inhibitor; Na+ K+ transporting ATPase inhibitor; Protein kinase inhibitor; Fibroblast growth factor receptor 2 antagonist; mTOR kinase inhibitor',\n",
       "       'Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; Phosphoribosylglycinamide formyltransferase inhibitor',\n",
       "       'Farnesyltransferase inhibitor; Cell cycle inhibitor; Apoptosis stimulant; Ras converting enzyme inhibitor',\n",
       "       'C-kit inhibitor; Colony stimulating factor 1 receptor antagonist; Flt-3 antagonist; Immuno-oncology therapy',\n",
       "       'Tubulin inhibitor; Angiogenesis inhibitor',\n",
       "       'CCK receptor antagonist', 'Toll-like receptor 3 agonist',\n",
       "       'Angiogenesis inhibitor; T cell stimulant; Natural killer cell stimulant',\n",
       "       'vimentin inhibitor',\n",
       "       'Hypoxia-inducible factor 2 alpha antagonist', 'BMI1 inhibitor',\n",
       "       'Amino acid transporter inhibitor; L-type amino acid transporter 1 inhibitor',\n",
       "       'C-kit inhibitor; RET tyrosine kinase inhibitor; FGF receptor tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; Angiogenesis inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Raf kinase inhibitor',\n",
       "       'Anaplastic lymphoma kinase inhibitor; ROS receptor tyrosine kinase inhibitor; Src inhibitor; TrkA tyrosine kinase inhibitor; TrkB tyrosine kinase inhibitor; TrkC tyrosine kinase inhibitor',\n",
       "       'Liver X receptor agonist; Immuno-oncology therapy',\n",
       "       'C-kit inhibitor; Platelet-derived growth factor receptor kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor',\n",
       "       'Immuno-oncology therapy; Immune checkpoint inhibitor; CD47 antagonist; Signal regulatory protein alpha antagonist',\n",
       "       'Poly ADP ribose polymerase 1 inhibitor; Poly ADP ribose polymerase 2 inhibitor; Poly ADP ribose polymerase 3 inhibitor',\n",
       "       'Protein kinase B inhibitor', 'Apoptosis stimulant',\n",
       "       'Quiescin sulfhydryl oxidase 1 inhibitor',\n",
       "       'STAT transcription factor 3 inhibitor; K-Ras inhibitor',\n",
       "       'Exportin 1 inhibitor', 'p53 stimulant',\n",
       "       'Casein kinase 2 inhibitor; Hedgehog pathway inhibitor',\n",
       "       'EphA receptor kinase inhibitor; Survivin inhibitor; Immuno-oncology therapy',\n",
       "       'Polo-like kinase 1 inhibitor', 'Hedgehog pathway inhibitor',\n",
       "       'B-raf kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; RET tyrosine kinase inhibitor; Flt-3 antagonist; Angiogenesis inhibitor; C-kit inhibitor; Raf kinase inhibitor; C-raf kinase inhibitor; Platelet-derived growth factor receptor beta kinase inhib',\n",
       "       'Hypoxia-inducible factor 1 alpha antagonist; Selective estrogen receptor modulator',\n",
       "       'ATF5 inhibitor; Transcription factor C/EBPbeta inhibitor',\n",
       "       'VEGFR tyrosine kinase inhibitor; Flt-3 antagonist; C-kit inhibitor; Colony stimulating factor 1 receptor antagonist; RET tyrosine kinase inhibitor; Angiogenesis inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Platelet-derived growth factor receptor beta kinase inhib; Platelet-derived growth factor receptor alpha kinase inhib',\n",
       "       'Granulocyte macrophage colony stimulating factor agonist; Immuno-oncology therapy',\n",
       "       'Placental growth factor inhibitor; Angiogenesis inhibitor',\n",
       "       'Immuno-oncology therapy; Interferon alpha antagonist',\n",
       "       'mTOR kinase inhibitor; Cell cycle inhibitor; Immunosuppressant; Protein kinase inhibitor',\n",
       "       'DNA inhibitor; DNA repair enzyme inhibitor; DNA topoisomerase II inhibitor; Mitotic inhibitor',\n",
       "       'Insulin-like growth factor 1 antagonist',\n",
       "       'Apoptosis stimulant; Survivin inhibitor; Cell cycle inhibitor; Cyclin-dependent kinase 1 inhibitor',\n",
       "       'EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Src inhibitor; EphB receptor kinase inhibitor',\n",
       "       'Tumour necrosis factor alpha antagonist; Angiogenesis inhibitor',\n",
       "       'Farnesyltransferase inhibitor; Angiogenesis inhibitor; Apoptosis stimulant',\n",
       "       'FLI1 inhibitor',\n",
       "       'Benzodiazepine receptor antagonist; DNA inhibitor; Ras inhibitor',\n",
       "       'Cytosine deaminase stimulant; Thymidylate synthase inhibitor; RNA synthesis inhibitor; Immuno-oncology therapy',\n",
       "       'PTEN stimulant',\n",
       "       'DNA inhibitor; DNA repair enzyme inhibitor; Apoptosis stimulant; Cell cycle inhibitor',\n",
       "       'Transforming growth factor beta 2 antagonist; Immuno-oncology therapy',\n",
       "       'Transforming growth factor beta 2 antagonist',\n",
       "       'ErbB-2 antagonist',\n",
       "       'MicroRNA inhibitor; Gene expression inhibitor', 'Reducing agent',\n",
       "       'CXC chemokine receptor 4 antagonist',\n",
       "       'Transforming growth factor beta receptor 1 antagonist',\n",
       "       'Immunostimulant; Angiogenesis inhibitor',\n",
       "       'VEGFR-2 tyrosine kinase inhibitor; RET tyrosine kinase inhibitor; EGFR kinase inhibitor; Angiogenesis inhibitor; VEGFR tyrosine kinase inhibitor',\n",
       "       'CD27 agonist; Immune checkpoint stimulant; Immuno-oncology therapy',\n",
       "       'B-raf kinase inhibitor; Protein kinase inhibitor',\n",
       "       'Isocitrate dehydrogenase 1 inhibitor; Isocitrate dehydrogenase 2 inhibitor',\n",
       "       'Leucine-rich repeat kinase 2 inhibitor', 'TTK kinase inhibitor',\n",
       "       'Thrombospondin 1 agonist; Angiogenesis inhibitor',\n",
       "       'Immuno-oncology therapy; Vascular endothelial growth factor receptor 2 antagonist; T cell stimulant',\n",
       "       'STAT transcription factor 3 inhibitor; Immuno-oncology therapy; PD-L1 antagonist; Hypoxia-inducible factor 1 alpha antagonist; Myc inhibitor; Immune checkpoint inhibitor',\n",
       "       'Cell cycle inhibitor', 'ErbB antagonist',\n",
       "       'Immuno-oncology therapy; CD137 agonist; Immune checkpoint stimulant',\n",
       "       'CXC chemokine receptor 4 antagonist; Immuno-oncology therapy',\n",
       "       'ROS receptor tyrosine kinase inhibitor; Trk tyrosine kinase inhibitor',\n",
       "       'Chitinase 3 like 1 inhibitor',\n",
       "       'Immuno-oncology therapy; Natural killer cell stimulant',\n",
       "       'Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 9 inhibitor; Flt-3 antagonist; Janus kinase 2 inhibitor; Mitogen-activated protein kinase 7 inhibitor'],\n",
       "      dtype=object)"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "table['Mechanism Of Action'].unique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "ename": "KeyError",
     "evalue": "'origin'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyError\u001b[0m                                  Traceback (most recent call last)",
      "\u001b[0;32m~/anaconda3/lib/python3.7/site-packages/pandas/core/indexes/base.py\u001b[0m in \u001b[0;36mget_loc\u001b[0;34m(self, key, method, tolerance)\u001b[0m\n\u001b[1;32m   2645\u001b[0m             \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 2646\u001b[0;31m                 \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_engine\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget_loc\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   2647\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0mKeyError\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32mpandas/_libs/index.pyx\u001b[0m in \u001b[0;36mpandas._libs.index.IndexEngine.get_loc\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32mpandas/_libs/index.pyx\u001b[0m in \u001b[0;36mpandas._libs.index.IndexEngine.get_loc\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32mpandas/_libs/hashtable_class_helper.pxi\u001b[0m in \u001b[0;36mpandas._libs.hashtable.PyObjectHashTable.get_item\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32mpandas/_libs/hashtable_class_helper.pxi\u001b[0m in \u001b[0;36mpandas._libs.hashtable.PyObjectHashTable.get_item\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;31mKeyError\u001b[0m: 'origin'",
      "\nDuring handling of the above exception, another exception occurred:\n",
      "\u001b[0;31mKeyError\u001b[0m                                  Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-24-3fcfccdbc21d>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mtable\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'origin'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;32m~/anaconda3/lib/python3.7/site-packages/pandas/core/frame.py\u001b[0m in \u001b[0;36m__getitem__\u001b[0;34m(self, key)\u001b[0m\n\u001b[1;32m   2798\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcolumns\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mnlevels\u001b[0m \u001b[0;34m>\u001b[0m \u001b[0;36m1\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   2799\u001b[0m                 \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_getitem_multilevel\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 2800\u001b[0;31m             \u001b[0mindexer\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcolumns\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget_loc\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   2801\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mis_integer\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mindexer\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   2802\u001b[0m                 \u001b[0mindexer\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0mindexer\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/lib/python3.7/site-packages/pandas/core/indexes/base.py\u001b[0m in \u001b[0;36mget_loc\u001b[0;34m(self, key, method, tolerance)\u001b[0m\n\u001b[1;32m   2646\u001b[0m                 \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_engine\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget_loc\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   2647\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0mKeyError\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 2648\u001b[0;31m                 \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_engine\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget_loc\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_maybe_cast_indexer\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   2649\u001b[0m         \u001b[0mindexer\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget_indexer\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mkey\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mmethod\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mmethod\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtolerance\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mtolerance\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   2650\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mindexer\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mndim\u001b[0m \u001b[0;34m>\u001b[0m \u001b[0;36m1\u001b[0m \u001b[0;32mor\u001b[0m \u001b[0mindexer\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msize\u001b[0m \u001b[0;34m>\u001b[0m \u001b[0;36m1\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32mpandas/_libs/index.pyx\u001b[0m in \u001b[0;36mpandas._libs.index.IndexEngine.get_loc\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32mpandas/_libs/index.pyx\u001b[0m in \u001b[0;36mpandas._libs.index.IndexEngine.get_loc\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32mpandas/_libs/hashtable_class_helper.pxi\u001b[0m in \u001b[0;36mpandas._libs.hashtable.PyObjectHashTable.get_item\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32mpandas/_libs/hashtable_class_helper.pxi\u001b[0m in \u001b[0;36mpandas._libs.hashtable.PyObjectHashTable.get_item\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;31mKeyError\u001b[0m: 'origin'"
     ]
    }
   ],
   "source": [
    "table['origin']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0      NaN\n",
       "1      NaN\n",
       "2      NaN\n",
       "3      NaN\n",
       "4      NaN\n",
       "      ... \n",
       "505    NaN\n",
       "506    NaN\n",
       "507    NaN\n",
       "508    NaN\n",
       "509    5.0\n",
       "Name: Rotatable Bonds, Length: 510, dtype: float64"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "table['Rotatable Bonds']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Generic Drug Name</th>\n",
       "      <th>Drug Names</th>\n",
       "      <th>Summary</th>\n",
       "      <th>Global Status</th>\n",
       "      <th>Development Status</th>\n",
       "      <th>Drug Disease</th>\n",
       "      <th>Company</th>\n",
       "      <th>Originator / Licensee</th>\n",
       "      <th>Company HQ Country</th>\n",
       "      <th>Company HQ State</th>\n",
       "      <th>...</th>\n",
       "      <th>Rotatable Bonds</th>\n",
       "      <th>Patent Number</th>\n",
       "      <th>Patent Priority Country &amp; Date</th>\n",
       "      <th>Marketing</th>\n",
       "      <th>Licensing</th>\n",
       "      <th>Phase III</th>\n",
       "      <th>Phase II</th>\n",
       "      <th>Phase I</th>\n",
       "      <th>Preclinical</th>\n",
       "      <th>Record URL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>177Lu-EBRGD, Molecular Targeting Technology</td>\n",
       "      <td>177Lu-EBRGD, Molecular Targeting Technology</td>\n",
       "      <td>177Lu-EBRGD is an integrin targeting radiother...</td>\n",
       "      <td>Preclinical</td>\n",
       "      <td>Active</td>\n",
       "      <td>Cancer, brain</td>\n",
       "      <td>Molecular Targeting Technology</td>\n",
       "      <td>Originator</td>\n",
       "      <td>USA</td>\n",
       "      <td>PA</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td></td>\n",
       "      <td>Agreements\\n________________\\n \\nNational Inst...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>https://citeline.informa.com/drugs/details/173...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>177Lu-FF-10158</td>\n",
       "      <td>177Lu FF 10158; 177LuFF10158; 177Lu-FF-10158</td>\n",
       "      <td>177Lu-FF-10158 is a targeted radioligand thera...</td>\n",
       "      <td>Preclinical</td>\n",
       "      <td>Active</td>\n",
       "      <td>Cancer, brain</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Originator</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td></td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>It is in preclinical development (Company Pipe...</td>\n",
       "      <td>https://citeline.informa.com/drugs/details/171...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2HIT medulloblastoma program, Oncoheroes</td>\n",
       "      <td>2HIT medulloblastoma program, Oncoheroes</td>\n",
       "      <td>Oncoheroes Biosciences is developing a repurpo...</td>\n",
       "      <td>Preclinical</td>\n",
       "      <td>Active</td>\n",
       "      <td>Cancer, brain</td>\n",
       "      <td>Oncoheroes Biosciences</td>\n",
       "      <td>Originator</td>\n",
       "      <td>USA</td>\n",
       "      <td>MA</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>It is at the discovery stage (Company Web Page...</td>\n",
       "      <td>https://citeline.informa.com/drugs/details/173...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3BP-227</td>\n",
       "      <td>177Lu-3BP-227; 177Lu-IPN01087; 3BP227; 3BP-227...</td>\n",
       "      <td>3BP-227 is a radio nuclear peptide based thera...</td>\n",
       "      <td>Phase II Clinical Trial</td>\n",
       "      <td>Active</td>\n",
       "      <td>Cancer, brain\\nCancer, brain</td>\n",
       "      <td>3B Pharmaceuticals\\nIpsen</td>\n",
       "      <td>Originator\\nLicensee</td>\n",
       "      <td>Germany\\nFrance</td>\n",
       "      <td>\\n</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Filings\\n________________\\n \\nCancer, pancreat...</td>\n",
       "      <td>Agreements\\n________________\\n \\nPancreatic Ca...</td>\n",
       "      <td>Cancer, pancreatic\\nIpsen\\nA Phase II/III prec...</td>\n",
       "      <td>Cancer, bone; Cancer, colorectal; Cancer, head...</td>\n",
       "      <td>Phase I trials were expected in 2017 (Company ...</td>\n",
       "      <td>It was in preclinical development for the trea...</td>\n",
       "      <td>https://citeline.informa.com/drugs/details/122...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>9-ING-41</td>\n",
       "      <td>9-ING 41; 9-ING41; 9-ING-41</td>\n",
       "      <td>9-ING-41 is a glycogen synthase kinase-3 (GSK-...</td>\n",
       "      <td>Phase II Clinical Trial</td>\n",
       "      <td>Active</td>\n",
       "      <td>Cancer, brain</td>\n",
       "      <td>Actuate Therapeutics</td>\n",
       "      <td>Originator</td>\n",
       "      <td>USA</td>\n",
       "      <td>TX</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Orphan Drug Status\\n________________\\n \\nCance...</td>\n",
       "      <td>Agreements\\n________________\\n \\nNorthwestern ...</td>\n",
       "      <td></td>\n",
       "      <td>Cancer, brain\\nA Phase I/II trial of 9-ING-41 ...</td>\n",
       "      <td>Cancer, solid, unspecified\\nIt is in an open-l...</td>\n",
       "      <td>In vivo\\nIn vivo xenograft studies, 9-ING-41 w...</td>\n",
       "      <td>https://citeline.informa.com/drugs/details/124...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>505</th>\n",
       "      <td>XZP-5955</td>\n",
       "      <td>XZP 5955; XZP5955; XZP-5955</td>\n",
       "      <td>XZP-5955 is a second generation pan-TRK/ROS1 d...</td>\n",
       "      <td>Preclinical</td>\n",
       "      <td>Active</td>\n",
       "      <td>Cancer, brain</td>\n",
       "      <td>Sihuan Pharmaceutical</td>\n",
       "      <td>Originator</td>\n",
       "      <td>China</td>\n",
       "      <td></td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>IND submission is expected by the end of 2020 ...</td>\n",
       "      <td>In vivo \\n \\nIn a BaF3 LMNA-TRKA G595R xenogra...</td>\n",
       "      <td>https://citeline.informa.com/drugs/details/182...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>506</th>\n",
       "      <td>YKL-40 inhibitor, OncoArendi Therapeutics</td>\n",
       "      <td>YKL-40 inhibitor, OncoArendi Therapeutics</td>\n",
       "      <td>OncoArendi Therapeutics is developing a YKL-40...</td>\n",
       "      <td>Preclinical</td>\n",
       "      <td>Active</td>\n",
       "      <td>Cancer, brain</td>\n",
       "      <td>OncoArendi Therapeutics</td>\n",
       "      <td>Originator</td>\n",
       "      <td>Poland</td>\n",
       "      <td></td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>It is in preclinical development (258th ACS (A...</td>\n",
       "      <td>https://citeline.informa.com/drugs/details/181...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>507</th>\n",
       "      <td>z-butylidenephthalide</td>\n",
       "      <td>butylidenephthalide; cerebraca wafer, Everfron...</td>\n",
       "      <td>Z-butylidenephthalide (Z-BP) under development...</td>\n",
       "      <td>Phase II Clinical Trial</td>\n",
       "      <td>Active</td>\n",
       "      <td>Cancer, brain\\nCancer, brain</td>\n",
       "      <td>Everfront Biotech\\nEverfront Biotech</td>\n",
       "      <td>Originator\\nOriginator</td>\n",
       "      <td>Taiwan\\nTaiwan</td>\n",
       "      <td>\\n</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Orphan Drug Status\\n________________\\n \\nCance...</td>\n",
       "      <td>Availability\\n________________\\n \\nEverfront B...</td>\n",
       "      <td></td>\n",
       "      <td>Cancer, brain\\nIt is in a Phase I/IIa trial (E...</td>\n",
       "      <td>A randomized, parallel, double-blind Phase I t...</td>\n",
       "      <td>In vivo\\nAnimal toxicity studies had been comp...</td>\n",
       "      <td>https://citeline.informa.com/drugs/details/116...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>508</th>\n",
       "      <td>ZM-008</td>\n",
       "      <td>ZM 008; ZM008; ZM-008</td>\n",
       "      <td>ZM-008 is an anti-LLT1 mAb NK cell-based thera...</td>\n",
       "      <td>Preclinical</td>\n",
       "      <td>Active</td>\n",
       "      <td>Cancer, brain</td>\n",
       "      <td>Zumutor Biologics</td>\n",
       "      <td>Originator</td>\n",
       "      <td>USA</td>\n",
       "      <td>MA</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>An IND filing is expected in the mid of 2021 a...</td>\n",
       "      <td>It is in preclinical development (Company pipe...</td>\n",
       "      <td>https://citeline.informa.com/drugs/details/158...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>509</th>\n",
       "      <td>zotiraciclib</td>\n",
       "      <td>CDK/Flt3 inhibitor, SBIO; EX-45; SB1317; SB-13...</td>\n",
       "      <td>Zotiraciclib (SB-1317) is the lead in a series...</td>\n",
       "      <td>Phase I Clinical Trial</td>\n",
       "      <td>Active</td>\n",
       "      <td>Cancer, brain\\nCancer, brain\\nCancer, brain\\nC...</td>\n",
       "      <td>Adastra Pharmaceuticals\\nAdastra Pharmaceutica...</td>\n",
       "      <td>Licensee\\nLicensee\\nLicensee\\nLicensee\\nOrigin...</td>\n",
       "      <td>USA\\nUSA\\nUSA\\nHong Kong\\nSingapore</td>\n",
       "      <td>CA\\nCA\\nCA\\n \\n</td>\n",
       "      <td>...</td>\n",
       "      <td>5.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Orphan Drug Status\\n________________\\n \\nCance...</td>\n",
       "      <td>Agreements\\n________________\\n \\nQualifying Th...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Cancer, brain\\nA Phase I trial in Europe and t...</td>\n",
       "      <td>In vivo\\nIn an ex vivo panel of malignant lymp...</td>\n",
       "      <td>https://citeline.informa.com/drugs/details/381...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>510 rows × 55 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                               Generic Drug Name  \\\n",
       "0    177Lu-EBRGD, Molecular Targeting Technology   \n",
       "1                                 177Lu-FF-10158   \n",
       "2       2HIT medulloblastoma program, Oncoheroes   \n",
       "3                                        3BP-227   \n",
       "4                                       9-ING-41   \n",
       "..                                           ...   \n",
       "505                                     XZP-5955   \n",
       "506    YKL-40 inhibitor, OncoArendi Therapeutics   \n",
       "507                        z-butylidenephthalide   \n",
       "508                                       ZM-008   \n",
       "509                                 zotiraciclib   \n",
       "\n",
       "                                            Drug Names  \\\n",
       "0          177Lu-EBRGD, Molecular Targeting Technology   \n",
       "1         177Lu FF 10158; 177LuFF10158; 177Lu-FF-10158   \n",
       "2             2HIT medulloblastoma program, Oncoheroes   \n",
       "3    177Lu-3BP-227; 177Lu-IPN01087; 3BP227; 3BP-227...   \n",
       "4                          9-ING 41; 9-ING41; 9-ING-41   \n",
       "..                                                 ...   \n",
       "505                        XZP 5955; XZP5955; XZP-5955   \n",
       "506          YKL-40 inhibitor, OncoArendi Therapeutics   \n",
       "507  butylidenephthalide; cerebraca wafer, Everfron...   \n",
       "508                              ZM 008; ZM008; ZM-008   \n",
       "509  CDK/Flt3 inhibitor, SBIO; EX-45; SB1317; SB-13...   \n",
       "\n",
       "                                               Summary  \\\n",
       "0    177Lu-EBRGD is an integrin targeting radiother...   \n",
       "1    177Lu-FF-10158 is a targeted radioligand thera...   \n",
       "2    Oncoheroes Biosciences is developing a repurpo...   \n",
       "3    3BP-227 is a radio nuclear peptide based thera...   \n",
       "4    9-ING-41 is a glycogen synthase kinase-3 (GSK-...   \n",
       "..                                                 ...   \n",
       "505  XZP-5955 is a second generation pan-TRK/ROS1 d...   \n",
       "506  OncoArendi Therapeutics is developing a YKL-40...   \n",
       "507  Z-butylidenephthalide (Z-BP) under development...   \n",
       "508  ZM-008 is an anti-LLT1 mAb NK cell-based thera...   \n",
       "509  Zotiraciclib (SB-1317) is the lead in a series...   \n",
       "\n",
       "               Global Status Development Status  \\\n",
       "0                Preclinical             Active   \n",
       "1                Preclinical             Active   \n",
       "2                Preclinical             Active   \n",
       "3    Phase II Clinical Trial             Active   \n",
       "4    Phase II Clinical Trial             Active   \n",
       "..                       ...                ...   \n",
       "505              Preclinical             Active   \n",
       "506              Preclinical             Active   \n",
       "507  Phase II Clinical Trial             Active   \n",
       "508              Preclinical             Active   \n",
       "509   Phase I Clinical Trial             Active   \n",
       "\n",
       "                                          Drug Disease  \\\n",
       "0                                        Cancer, brain   \n",
       "1                                        Cancer, brain   \n",
       "2                                        Cancer, brain   \n",
       "3                         Cancer, brain\\nCancer, brain   \n",
       "4                                        Cancer, brain   \n",
       "..                                                 ...   \n",
       "505                                      Cancer, brain   \n",
       "506                                      Cancer, brain   \n",
       "507                       Cancer, brain\\nCancer, brain   \n",
       "508                                      Cancer, brain   \n",
       "509  Cancer, brain\\nCancer, brain\\nCancer, brain\\nC...   \n",
       "\n",
       "                                               Company  \\\n",
       "0                       Molecular Targeting Technology   \n",
       "1                                             Novartis   \n",
       "2                               Oncoheroes Biosciences   \n",
       "3                            3B Pharmaceuticals\\nIpsen   \n",
       "4                                 Actuate Therapeutics   \n",
       "..                                                 ...   \n",
       "505                              Sihuan Pharmaceutical   \n",
       "506                            OncoArendi Therapeutics   \n",
       "507               Everfront Biotech\\nEverfront Biotech   \n",
       "508                                  Zumutor Biologics   \n",
       "509  Adastra Pharmaceuticals\\nAdastra Pharmaceutica...   \n",
       "\n",
       "                                 Originator / Licensee  \\\n",
       "0                                           Originator   \n",
       "1                                           Originator   \n",
       "2                                           Originator   \n",
       "3                                 Originator\\nLicensee   \n",
       "4                                           Originator   \n",
       "..                                                 ...   \n",
       "505                                         Originator   \n",
       "506                                         Originator   \n",
       "507                             Originator\\nOriginator   \n",
       "508                                         Originator   \n",
       "509  Licensee\\nLicensee\\nLicensee\\nLicensee\\nOrigin...   \n",
       "\n",
       "                      Company HQ Country  Company HQ State  ...  \\\n",
       "0                                    USA                PA  ...   \n",
       "1                            Switzerland                    ...   \n",
       "2                                    USA                MA  ...   \n",
       "3                        Germany\\nFrance               \\n   ...   \n",
       "4                                    USA                TX  ...   \n",
       "..                                   ...               ...  ...   \n",
       "505                                China                    ...   \n",
       "506                               Poland                    ...   \n",
       "507                       Taiwan\\nTaiwan               \\n   ...   \n",
       "508                                  USA                MA  ...   \n",
       "509  USA\\nUSA\\nUSA\\nHong Kong\\nSingapore  CA\\nCA\\nCA\\n \\n   ...   \n",
       "\n",
       "    Rotatable Bonds Patent Number Patent Priority Country & Date  \\\n",
       "0               NaN           NaN                            NaN   \n",
       "1               NaN           NaN                            NaN   \n",
       "2               NaN           NaN                            NaN   \n",
       "3               NaN           NaN                            NaN   \n",
       "4               NaN           NaN                            NaN   \n",
       "..              ...           ...                            ...   \n",
       "505             NaN           NaN                            NaN   \n",
       "506             NaN           NaN                            NaN   \n",
       "507             NaN           NaN                            NaN   \n",
       "508             NaN           NaN                            NaN   \n",
       "509             5.0           NaN                            NaN   \n",
       "\n",
       "                                             Marketing  \\\n",
       "0                                                        \n",
       "1                                                        \n",
       "2                                                        \n",
       "3    Filings\\n________________\\n \\nCancer, pancreat...   \n",
       "4    Orphan Drug Status\\n________________\\n \\nCance...   \n",
       "..                                                 ...   \n",
       "505                                                      \n",
       "506                                                      \n",
       "507  Orphan Drug Status\\n________________\\n \\nCance...   \n",
       "508                                                      \n",
       "509  Orphan Drug Status\\n________________\\n \\nCance...   \n",
       "\n",
       "                                             Licensing  \\\n",
       "0    Agreements\\n________________\\n \\nNational Inst...   \n",
       "1                                                        \n",
       "2                                                        \n",
       "3    Agreements\\n________________\\n \\nPancreatic Ca...   \n",
       "4    Agreements\\n________________\\n \\nNorthwestern ...   \n",
       "..                                                 ...   \n",
       "505                                                      \n",
       "506                                                      \n",
       "507  Availability\\n________________\\n \\nEverfront B...   \n",
       "508                                                      \n",
       "509  Agreements\\n________________\\n \\nQualifying Th...   \n",
       "\n",
       "                                             Phase III  \\\n",
       "0                                                        \n",
       "1                                                        \n",
       "2                                                        \n",
       "3    Cancer, pancreatic\\nIpsen\\nA Phase II/III prec...   \n",
       "4                                                        \n",
       "..                                                 ...   \n",
       "505                                                      \n",
       "506                                                      \n",
       "507                                                      \n",
       "508                                                      \n",
       "509                                                      \n",
       "\n",
       "                                              Phase II  \\\n",
       "0                                                        \n",
       "1                                                        \n",
       "2                                                        \n",
       "3    Cancer, bone; Cancer, colorectal; Cancer, head...   \n",
       "4    Cancer, brain\\nA Phase I/II trial of 9-ING-41 ...   \n",
       "..                                                 ...   \n",
       "505                                                      \n",
       "506                                                      \n",
       "507  Cancer, brain\\nIt is in a Phase I/IIa trial (E...   \n",
       "508                                                      \n",
       "509                                                      \n",
       "\n",
       "                                               Phase I  \\\n",
       "0                                                        \n",
       "1                                                        \n",
       "2                                                        \n",
       "3    Phase I trials were expected in 2017 (Company ...   \n",
       "4    Cancer, solid, unspecified\\nIt is in an open-l...   \n",
       "..                                                 ...   \n",
       "505  IND submission is expected by the end of 2020 ...   \n",
       "506                                                      \n",
       "507  A randomized, parallel, double-blind Phase I t...   \n",
       "508  An IND filing is expected in the mid of 2021 a...   \n",
       "509  Cancer, brain\\nA Phase I trial in Europe and t...   \n",
       "\n",
       "                                           Preclinical  \\\n",
       "0                                                        \n",
       "1    It is in preclinical development (Company Pipe...   \n",
       "2    It is at the discovery stage (Company Web Page...   \n",
       "3    It was in preclinical development for the trea...   \n",
       "4    In vivo\\nIn vivo xenograft studies, 9-ING-41 w...   \n",
       "..                                                 ...   \n",
       "505  In vivo \\n \\nIn a BaF3 LMNA-TRKA G595R xenogra...   \n",
       "506  It is in preclinical development (258th ACS (A...   \n",
       "507  In vivo\\nAnimal toxicity studies had been comp...   \n",
       "508  It is in preclinical development (Company pipe...   \n",
       "509  In vivo\\nIn an ex vivo panel of malignant lymp...   \n",
       "\n",
       "                                            Record URL  \n",
       "0    https://citeline.informa.com/drugs/details/173...  \n",
       "1    https://citeline.informa.com/drugs/details/171...  \n",
       "2    https://citeline.informa.com/drugs/details/173...  \n",
       "3    https://citeline.informa.com/drugs/details/122...  \n",
       "4    https://citeline.informa.com/drugs/details/124...  \n",
       "..                                                 ...  \n",
       "505  https://citeline.informa.com/drugs/details/182...  \n",
       "506  https://citeline.informa.com/drugs/details/181...  \n",
       "507  https://citeline.informa.com/drugs/details/116...  \n",
       "508  https://citeline.informa.com/drugs/details/158...  \n",
       "509  https://citeline.informa.com/drugs/details/381...  \n",
       "\n",
       "[510 rows x 55 columns]"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
